The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia
Open accessAbstract
Acute myeloid leukemia (AML) is a hematopoietic disorder in which there are too many immature blood-forming cells accumulating in the bone marrow and interfering with the production of normal blood cells. It has long been recognized that AML is a clinically heterogeneous disease characterized by a multitude of chromosomal abnormalities and gene mutations, which translate to marked differences in responses and survival following chemotherapy. The cytogenetic and molecular genetic aberrations associated with AML are not mutually exclusive and often coexist in the leukemic cells. AML is a disease of the elderly, with a mean age of diagnosis of 70 years. Adverse cytogenetic abnormalities increase with age, and within each cytogenetic group, prognosis with standard treatment worsens with age. In the past 20 years, there has been little improvement in chemotherapeutic regimens and hence the overall survival for patients with AML. A huge unmet need exists for efficacious targeted therapies for elderly patients that are less toxic than available chemotherapy regimens. The multitude of chromosomal and genetic abnormalities makes the treatment of AML a challenging prospect. A detailed understanding of the molecular changes associated with the chromosomal and genetic abnormalities in AML is likely to provide a rationale for therapy design and biomarker development. This review summarizes the variety of cytogenetic and genetic changes observed in AML and gives an overview of the clinical status of new drugs in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
MLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
Melnick, A., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,028
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Grisendi, S., Mecucci, C., Falini, B., & Pandolfi, P. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1885 · Cited by 850
Preston, D. L., Kusumi, S., Tomonaga, M., Izumi, S., Ron, E., Kuramoto, A., Kamada, N., Dohy, H., Matsui, T., Nonaka, H., et al. (1994) · Radiation Research · doi:10.2307/3578893 · Cited by 803
Paschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., et al. (2005) · Blood · doi:10.1182/blood-2004-03-0891 · Cited by 657
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 418
Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S., Chopra, R., Clark, R., Levis, M. J., & Small, D. (2006) · Blood · doi:10.1182/blood-2006-04-015560 · Cited by 413
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
Meyers, S., Lenny, N., & Hiebert, S. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1974 · Cited by 368
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Farag, S. S., Archer, K. J., Mrózek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. B., Koduru, P. R., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4354 · Cited by 334
C/EBPα mutations in acute myeloid leukaemias
Nerlov, C. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1363 · Cited by 280
Core-binding factors in hematopoiesis and immune function
de Bruijn, M. F., & Speck, N. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207763 · Cited by 231
Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation
Lutterbach, B., & Hiebert, S. W. (2000) · Gene · doi:10.1016/s0378-1119(00)00014-7 · Cited by 209
Shipley, J. L., & Butera, J. N. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.04.002 · Cited by 200
(1995) · PubMed · Cited by 198
Davis, J. N., McGhee, L., & Meyers, S. (2003) · Gene · doi:10.1016/s0378-1119(02)01172-1 · Cited by 160
The role of MLL in hematopoiesis and leukemia
Ernst, P., Wang, J., & Korsmeyer, S. J. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00004 · Cited by 157
The Runx genes: lineage-specific oncogenes and tumor suppressors
Cameron, E. R., & Neil, J. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207130 · Cited by 155
Löwenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H. C., Verdonck, L. F., Ferrant, A., Sonneveld, P., Jongen‐Lavrencic, M., von Lilienfeld‐Toal, M., et al. (2010) · Blood · doi:10.1182/blood-2009-10-246470 · Cited by 145
Chemokines, chemokine receptors and hematopoiesis
Youn, B., Mantel, C., & Broxmeyer, H. E. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17701.x · Cited by 139
Deschler-Baier, B., de Witte, T., Mertelsmann, R. H., & Lübbert, M. (2006) · PubMed · Cited by 138
Tyner, J. W., Erickson, H., Deininger, M. W., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., et al. (2008) · Blood · doi:10.1182/blood-2008-04-152157 · Cited by 137
Therapy Related Leukemias: Susceptibility, Prevention and Treatment
Leone, G. G. M., Voso, M. T., Sica, S., Roberta Morosetti, A., & Pagano, L. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057981 · Cited by 132
A phase 2 study of vorinostat in acute myeloid leukemia
Schaefer, É., Loaiza‐Bonilla, A., Juckett, M. B., DiPersio, J. F., Roy, V., Slack, J. L., Wu, W., Laumann, K. M., Espinoza‐Delgado, I., & Gore, S. D. (2009) · Haematologica · doi:10.3324/haematol.2009.009217 · Cited by 128
The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor
Lutterbach, B. A., Hou, Y., Durst, K. L., & Hiebert, S. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12822 · Cited by 122
The molecular signature of oncofusion proteins in acute myeloid leukemia
Martens, J. H. A., & Stunnenberg, H. G. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.002 · Cited by 112
Acute Myelogenous Leukemia in Older Adults
Klepin, H. D., & Balducci, L. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0224 · Cited by 89
Targeting FLT3 for the Treatment of Leukemia
Small, D. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.07.007 · Cited by 87
Lima, M. J. G. D., Strom, S. S., Keating, M. J., et al. (1997) · Blood · doi:10.1182/blood.v90.12.4719 · Cited by 84
Mrózek, K., Döhner, H., & Bloomfield, C. D. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32801684c7 · Cited by 84
West, R. R., Stafford, D. A., White, A. D., Bowen, D., & Padua, R. A. (2000) · Blood · doi:10.1182/blood.v95.6.2093 · Cited by 79
Faderl, S. H., Ravandi, F., Huang, X., et al. (2012) · Cancer · doi:10.1002/cncr.27429 · Cited by 60
Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities
Pedersen-Bjergaard, J., Christiansen, D., Andersen, M., & Skovby, F. (2002) · Leukemia · doi:10.1038/sj.leu.2402764 · Cited by 57
Molecular Pathogenesis of MLL-Associated Leukemias
Eguchi, M., Eguchi‐Ishimae, M., & Greaves, M. F. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05042 · Cited by 51
Molecular signatures in acute myeloid leukemia
Mrózek, K., Radmacher, M. D., Bloomfield, C. D., & Marcucci, G. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257b42 · Cited by 51
Review: genetic models of acute myeloid leukaemia
McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2008) · Oncogene · doi:10.1038/onc.2008.16 · Cited by 50
Schlenk, R. F., Fröhling, S., Hartmann, F., Fischer, J. T., Glasmacher, A. G., del Valle, F., Götze, K. S. S., Nerl, C., Schoch, R., Pralle, H., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404122 · Cited by 43
Targeted therapy in acute myeloid leukaemia: current status and future directions
Stapnes, C., Gjertsen, B. T., Reikvam, H., & Bruserud, Ø. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220902787628 · Cited by 38
Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia
Didier, C., Cavelier, C., Quaranta, M., Demur, C., & Ducommun, B. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.062 · Cited by 26
Al‐Kali, A., Cortes, J. E., Faderl, S. H., Jones, D. M., Abril, C., Pierce, S. A., Brandt, M., Kantarjian, H. M., & Ravandi, F. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.06.007 · Cited by 25
Optimizing Therapy for Acute Myeloid Leukemia
Kohrt, H. E. K., & Coutre, S. E. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0076 · Cited by 21
Lestaurtinib: a multi-targeted FLT3 inhibitor
Fathi, A. T., & Levis, M. J. (2009) · Expert Review of Hematology · doi:10.1586/17474086.2.1.17 · Cited by 21
Has there been progress in the treatment of older patients with acute myeloid leukemia?
Erba, H. P. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.09.012 · Cited by 18
Treatment of Acute Myeloid Leukemia with Hematopoietic Stem Cell Transplantation
Jones, C. V., & Copelan, E. A. (2009) · Future Oncology · doi:10.2217/fon.09.20 · Cited by 10
Szotkowski, T., Mužı́k, J., Voglová, J., Koza, V., Maaloufová, J., Kozák, T., Jarošová, M., Michalova, K., Зак, П., Steinerová, K., et al. (2010) · Neoplasma · doi:10.4149/neo_2010_06_578 · Cited by 10
Acute Myeloid Leukemia in Adults
Appelbaum, F. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50108-1 · Cited by 10
Sekeres, M. A., Gundacker, H. M., Lancet, J. E., Advani, A. S., Petersdorf, S. H., Liesveld, J. L., Mulford, D. A., Norwood, T., Willman, C. L., List, A. F., et al. (2010) · Blood · doi:10.1182/blood.v116.21.332.332 · Cited by 8
(1996) · PubMed
Cited by
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
Tsuruta-Kishino, T., Koya, J., Kataoka, K., Narukawa, K., Sumitomo, Y., Kobayashi, H., Sato, T., & Kurokawa, M. (2017) · Oncogene · doi:10.1038/onc.2016.478 · Cited by 41
Small Non-Coding RNAs in Leukemia
Balatti, V., & Croce, C. M. (2022) · Cancers · doi:10.3390/cancers14030509 · Cited by 14
Metadata
- Authors
- Kumar, C. C.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-02-01
- Volume
- 2
- Issue
- 2
- Pages
- 95-107
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2102423175
- Cited by
- 272
- References
- 61
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.